Candida Vulvovaginitis

3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Scynexis
ScynexisJERSEY CITY, NJ
3 programs
1
2
IbrexafungerpPhase 31 trial
IbrexafungerpPhase 31 trial
FluconazolePhase 2Small Molecule1 trial
Active Trials
NCT03253094CompletedEst. May 2018
NCT03734991CompletedEst. Sep 2019
NCT03987620CompletedEst. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ScynexisIbrexafungerp
ScynexisIbrexafungerp
ScynexisFluconazole

Clinical Trials (3)

NCT03987620ScynexisIbrexafungerp

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Start: Jun 2019Est. completion: Apr 2020
Phase 3Completed
NCT03734991ScynexisIbrexafungerp

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Start: Jan 2019Est. completion: Sep 2019
Phase 3Completed
NCT03253094ScynexisFluconazole

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Start: Aug 2017Est. completion: May 2018
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space